Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma

Trial Profile

Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs ACTR707 (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Unum Therapeutics
  • Most Recent Events

    • 30 Oct 2017 Trial design presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
    • 04 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 21 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top